IL18 and congenital rubella syndrome: Free IL-18 was differentially elevated in patients with CRS and IEC-HS compared to those with CRS alone (117) and may warrant investigation of agents targeting this pathway such as tadekinig alfa, a human recombinant IL-18-binding protein, which is not currently FDA approved.